Cargando…
Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study
BACKGROUND: Proliferative activity (Ki-67 Labelling Index) in breast cancer increasingly serves as an additional tool in the decision for or against adjuvant chemotherapy in midrange hormone receptor positive breast cancer. Ki-67 Index has been previously shown to suffer from high inter-observer var...
Autores principales: | Varga, Zsuzsanna, Cassoly, Estelle, Li, Qiyu, Oehlschlegel, Christian, Tapia, Coya, Lehr, Hans Anton, Klingbiel, Dirk, Thürlimann, Beat, Ruhstaller, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401515/ https://www.ncbi.nlm.nih.gov/pubmed/25885288 http://dx.doi.org/10.1371/journal.pone.0123435 |
Ejemplares similares
-
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
por: Varga, Zsuzsanna, et al.
Publicado: (2019) -
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
por: Eppenberger-Castori, Serenella, et al.
Publicado: (2020) -
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
por: Maranta, Angela Fischer, et al.
Publicado: (2020) -
How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists
por: Varga, Zsuzsanna, et al.
Publicado: (2012) -
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
por: Schmid, Sabine, et al.
Publicado: (2019)